S. Kobernick and J. Whiteside, Renal glomeruli in multiple myeloma Laboratory investigation; a journal of technical methods and pathology, pp.478-8501, 1957.

L. Sanchez, . Domz, and . Ca, Renal patterns in myeloma Annals of internal medicine, TT A. Light chain deposits in multiple myeloma. Laboratory Investigation, pp.44-54, 1960.

R. Randall, W. Williamson, J. Mullinax, F. Tung, M. Still et al., Manifestations of systemic light chain deposition. The American journal of medicine, pp.293-901, 1976.

F. Bridoux, N. Leung, C. Hutchison, G. Touchard, S. Sethi et al., Diagnosis of monoclonal gammopathy of renal significance. Kidney international, 2015.

J. Lin, G. Markowitz, A. Valeri, N. Kambham, W. Sherman et al., Renal monoclonal immunoglobulin deposition disease: the disease spectrum Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution, Journal of the American Society of Nephrology : JASN. Clinical, vol.127, issue.7, pp.1482-92, 2001.

C. Pozzi, D. Amico, M. Fogazzi, G. Curioni, S. Ferrario et al., Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors, American Journal of Kidney Diseases, vol.42, issue.6
DOI : 10.1053/j.ajkd.2003.08.040

J. Aucouturier, P. Touchard, G. Striker, L. Khamlichi, A. Rocca et al., Monoclonal immunoglobulin deposition disease (Randall type) Relationship with structural abnormalities of immunoglobulin chains. Kidney international Epub 1994/10/01. 10 Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association -European Renal Association Overrepresentation of the V kappa IV subgroup in light chain deposition disease, American journal of kidney diseases : the official journal of the National Kidney Foundation, pp.1154-63965, 1994.

V. Bellotti, M. Stoppini, G. Merlini, M. Zapponi, M. Meloni et al., Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease Biochimica et biophysica acta Primary structure of a variable region of the V kappa I subgroup (ISE) in light chain deposition disease, Clinical and experimental immunology, vol.10979101, issue.33, pp.177-82506, 1991.

D. Ganeval, L. Noel, J. Preud-'homme, D. Droz, J. Grunfeld et al., Light-chain deposition disease: its relation with AL-type amyloidosis Kidney international Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1 Brief report: heavy-chain deposition disease Structure of abnormal heavy chains in human heavy-chain-deposition disease Pathogenesis of glomerulosclerosis in light chain deposition disease Role for transforming growth factor-beta, Journal of the American Society of Nephrology : JASN. The New England journal of medicine. Epub European journal of biochemistry / FEBS, vol.261012329229, issue.191, pp.1-9519, 1984.

F. Bridoux, R. Kyle, E. Kastritis, B. Weiss, and M. Cook, Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant How I treat monoclonal gammopathy of renal significance (MGRS), Blood. Blood, vol.12012210, issue.24, pp.4292-53583, 2012.

B. Alchi, S. Nishi, S. Iguchi, M. Shimotori, M. Sakatsume et al., Recurrent light and heavy chain deposition disease after renal transplantation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Renal transplantation in light chain nephropathy: case report and review of the literature, Epub Clinical nephrology, vol.2025, issue.72, pp.1487-91101, 1986.

K. Horike, A. Takeda, Y. Otsuka, D. Inaguma, N. Goto et al., A case of recurrent light chain deposition disease after living-related renal transplantation -detailed process of the recurrence Long-term outcome of renal transplantation in light-chain deposition disease American journal of kidney diseases : the official journal of the National Kidney Foundation Lambda light chain deposition disease in a renal allograft High dose chemotherapy in light chain or light and heavy chain deposition disease, Clinical transplantation. Transplantation proceedings. Epub Kidney international, vol.26433765, issue.292, pp.64-9147, 2004.

B. Telio, D. Shepherd, J. Forrest, D. Zypchen, L. Barnett et al., 32. Petrakis I Biopsyproven resolution of renal light-chain deposition disease after autologous stem cell transplantation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association -European Renal Association Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report Self-compartmentalizing proteases. Trends in biochemical sciences The proteasome: paradigm of a selfcompartmentalizing protease Regulatory subunits of energy-dependent proteases Protein translocation channels in the proteasome and other proteases Fukasawa H. The role of the ubiquitin-proteasome system in kidney diseases Ubiquitin-mediated proteolysis of vertebrate G1-and S-phase regulators Role and function of the 26S proteasome in proliferation and apoptosis. Laboratory investigation; a journal of technical methods and pathology The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras Signalinduced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer research A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Annals of internal medicine, Epub 1999/03/13. 49. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American journal of kidney diseases : the official journal of the National Kidney Foundation 50. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, pp.340-4453, 1994.

B. Durie, J. Harousseau, J. Miguel, J. Blade, B. Barlogie et al., Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia, Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report, pp.1467-73110, 1994.

P. Proteasome-inhibitor, C. Mitsiades, P. Richardson, V. Poulaki, Y. Tai et al., The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology A phase 2 study of bortezomib in relapsed, refractory myeloma Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge. Transplant international : official journal of the European Society for Organ Transplantation Use of bortezomib in heavy-chain deposition disease: a report of 3 cases, Blood. The New England journal of medicine. American journal of kidney diseases : the official journal of the National Kidney Foundation. Haematologica, vol.621011222348286499, issue.6126319, pp.4996-50002377, 2002.

. Cyclophosphamide-bortezomib-dexamethasone, CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis, Blood, vol.119, pp.4391-4395, 2012.

. Cyclophosphamide, Epub 2012/02/15. 44 RESUMES ET MOT CLES Résumé français La maladie des dépôts d'immunoglobulines monoclonales (MDIM) est une complication rare des proliférations plasmocytaires monoclonales, définie par des dépôts rouge Congo négatifs, de chaînes légères (LCDD), lourdes (HCDD), ou les 2 (LHCDD), le long des membranes basales. L'atteinte rénale est quasi constante. Les stratégies thérapeutiques, pp.4387-90, 2012.

M. Dans-les, les traitements à base de bortezomib apparaissent sûres et efficaces quand introduits de manière précoce. La réponse hématologique basée sur la dFLC est un facteur pronostique

F. Mots, Maladie des dépôts d'immunoglobulines monoclonales, gammapathie monoclonale de signification rénale, immunoglobuline monoclonale, bortezomib

M. In, bortezomib-based therapy is safe and efficient when introduced early after diagnosis. dFLC response is a favorable prognostic factor for renal survival